White label ELPA - ClinicalTrials.eu

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Bisoprolol in Patients After Myocardial Infarction with Preserved Ejection Fraction During Cardiac Rehabilitation

Recruiting

3 1 1 1
Investigated Diseases:
- Heart failure with preserved ejection fraction
- Acute myocardial infarction
Investigated Drugs:
- Bisoprolol
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Recruiting

3 1

+14
Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Recruiting

3 1
Investigated Diseases:
- Systemic lupus erythematosus
Investigated Drugs:
- Nipocalimab
+9
BMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer

Recruiting

2 1 1 1
Investigated Drugs:
- Nivolumab
NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

Recruiting

2 1 1
Investigated Drugs:
JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

Recruiting

3 1 1
Investigated Drugs:
- Teclistamab
- IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
+1
Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Recruiting

2 1 1 1
Investigated Drugs:
- Asciminib Hydrochloride
+2
Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

Recruiting

2 1 1
Investigated Diseases:
- Neoplasm
Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting

3 1 1 1
Investigated Drugs:
+8

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies